Shankar Siva, MBBS, PhD, FRANZCR, discussed when to consider cytoreductive SABR in patients with metastatic kidney cancer responding to systemic therapy.
News|Articles|September 30, 2024
IMRT Yields Similar QOL Vs Proton Therapy in Localized Prostate Cancer
Author(s)Russ Conroy
Fact checked by: Harrison Widelitz
Data show no differences in bowel function between treatment arms based on factors including age, disease risk, and fractionation schedule.
Advertisement
Advertisement
Intensity-modulated radiation therapy (IMRT) and proton beam therapy yielded comparable quality of life (QOL) outcomes and effective tumor control among patients with localized prostate cancer, according to findings from the phase 3 Prostate Advanced Radiation Technologies Investigating Quality of Life (PARTIQoL) trial (NCT01617161) presented in a press briefing at the
Related to this article
Bhanu Prasad Venkatesulu, MBBS, MD, discussed why fewer radiation oncologists perform brachytherapy, and one setting where he considers it the better option.
Bhanu Prasad Venkatesulu, MBBS, MD, discussed why fewer radiation oncologists offer prostate brachytherapy and the patients for whom he still recommends it.
Adam C. Olson, MD, MSc-GH, discussed letting patients choose between modalities with comparably strong evidence and the data that shaped his approach.
Adam C. Olson, MD, MSc-GH, discussed the infrastructure, training, and shared decision-making behind building a prostate HDR brachytherapy program.
Tyler J. Wilhite, MD, discussed coordinating with rheumatology, orthopedic surgery, and primary care when treating patients with osteoarthritis with low-dose radiation therapy.
Tyler J. Wilhite, MD, discussed scaling low-dose radiation therapy for osteoarthritis from 1 patient to nearly 20 centers and the referral work behind it.
Parul N. Barry, MD, FACRO, discussed building programs early in a career and used low-dose radiotherapy and aromatase inhibitor tolerance to show how to demonstrate value.
Advertisement
Advertisement